News

Ryzodeg is a combination of insulin degludec and insulin aspart in the ratio of 70% and 30%, respectively. It is the first combination of a basal insulin with

In the US, Vimpat is already approved as adjunctive treatment for partial-onset seizures in patients belonging to this age group. The new indication means that adults aged 17

The trial evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). During the 12-month extended

The trial evaluated 96 New York Heart Association (NYHA) Class II-III patients with heart failure and an ejection fraction of less than 35%. During the trial, all patients

This study was a 10-year epidemiology study, conducted by the University of Pennsylvania and Division of Research at Kaiser Permanente Northern California (KPNC), and was designed to investigate

The tender offer is being made pursuant to the previously announced merger agreement dated 22 August 2014 among Roche Holdings, Inc., Klee Acquisition Corporation, a wholly owned subsidiary

Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). Results from the four ongoing trials, all of which met their primary efficacy endpoint, will

QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by Centre for Disease

New trials will investigate rivaroxaban, the most studied Factor Xa inhibitor, for the treatment of acute coronary syndrome (ACS), embolic stroke of undetermined source (ESUS) and peripheral artery